Liminatus Pharma (LIMN) vs NuCana (NCNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Liminatus Pharma is the larger company by market cap ($5.0 million vs $4.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LIMN | NCNA |
|---|---|---|
| Share price | $3.69 | $1.13 |
| Market cap | $4.96M | $4.70M |
| 1-day change | -4.65% | -0.88% |
| EPS (TTM) | $-23.50 | $0.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $141.50 | $6.40 |
| 52-week low | $3.29 | $0.948 |
| Distance from 52-week high | -97.39% | -82.34% |
| Average volume | 453.28K | 123.99K |
| Shares outstanding | 1.34M | 4.16M |
| Employees | 1 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Liminatus Pharma
LIMN stock →Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1 employees
About NuCana
NCNA stock →NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
LIMN vs NCNA FAQ
Which is bigger, Liminatus Pharma or NuCana?
Liminatus Pharma (LIMN) is larger, with a market capitalization of $4.96M compared with $4.70M for NuCana (NCNA).
Are Liminatus Pharma and NuCana in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Liminatus Pharma and Biotechnology: Pharmaceutical Preparations for NuCana.